Drug Information Archives - Page 3 of 61 - Oncology Nurse Advisor

Drug Information

Talimogene Laherparepvec (Imlygic)

  This slideshow reviews talimogene laherparepvec (Imlygic), indicated for unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery/ Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 26: Reference   

Next post in Multiple Myeloma